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1. Introduction 
Infection with human immune deficiency virus (HIV) is a challenging problem to public 
health, because it often involves long term treatment with advanced drugs to prolong survival 
of patients diagnosed with the infection. As an important public health preventive measure, it 
is necessary to give an HIV-infected individual antiretroviral  therapy (ART). This measure 
facilitates the reduction of the risk of the infected individual from transmitting the virus to 
others by reducing the viral load in that person. But often, the drug regimens used are 
surrounded by such questions as the best timing for initiation of therapy as well as benefits 
and risks associated with delay or early treatment. As a result health caregivers for HIV need 
to have a continuous update of their knowledge and skills on HIV care and counseling so that 
they can manage and support individuals with HIV/AIDS with the best and most effective 
strategy. One way to develop an effective preventive response against HIV is to understand 
how the infection spreads and the factors that contribute to new infections.  
Data from epidemiological studies indicate that, worldwide the prevalence of HIV increased 
from 29 million in 2001 to 33.4 million in 2008. Similarly, other opportunistic infections such 
as tuberculosis, cryptococcal meningitis as well as the drug-resistant forms of these diseases 
altogether add up to make the management of HIV a complex activity. Whereas the 
incidence is declining in many parts of the world due to access to effective drug regimens, 
the trend in developing countries has stabilized or slightly increased. Available data from 11 
West African countries indicate that national prevalence of HIV/AIDS had been stable in 
these countries ranging from <1% in Senegal and Niger, to 6.7% in Guinea Bissau. With the 
exception of Senegal and Ghana, the prevalence rates of these countries were higher in the 
urban than in the rural areas. The spread of HIV in this region is of great concern to many 
organizations and governments because of predictions of its increase, yet data are scarce 
and not regularly revised to reflect current estimates for the countries in this region. In 
addition, there is the presence of both HIV-1 and HIV-2 in this region. Though more 
importance is placed on the former than the latter because it is thought to be more easily 
transmissible while conflicting reports have been shown for the later regarding its 
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protection of HIV-1 and a lower progression to disease. There is great enthusiasm by many 
stakeholders in  establishing preventive measures to control increase in HIV-1 in the region, 
however, not much is done about estimation of transmission dynamics and monitoring of 
coverage of interventions.  
In Mali, estimates from 2006 indicated that the overall prevalence of HIV was 1.3% in the 
general population, 2.2% among young adults (between the ages of 15 and 30), and 35.3% 
among sex workers  (Samake, 2006). The main factors associated with HIV infection in Mali 
are limited access to treatment and extreme poverty. However, other factors such as poor 
health conditions, low literacy levels and certain cultural practices like male dominance of 
women, low condom use, and a relatively high prevalence of sexually transmitted diseases, 
all contribute to HIV transmission in Mali. Here, we review some of the preventive methods 
adopted for the management of HIV in Mali. Our review includes current epidemiological 
data in the general population and the different forms of circulating HIV strains as well as 
HIV transmission risk behaviors among patients diagnosed with HIV infection in Mali. We 
also discuss progress made with effective distribution of drug regimens and throw light on 
the debates of when to start therapy as well as the benefits and demerits of these measures. 
2. Epidemiology 
2.1 Overview of HIV infection in Mali 
Mali is a landlocked country situated in West Africa with a size of 1,241,248 Km2 and a 
population of approximately 14.5 million inhabitants. The country is divided into 8 
administrative regions with Bamako as the capital. The north stretches deep into the Sahara 
and is inhabited mainly by the Tuaregs and the nomadic Fulani tribes. Two major rivers, 
Niger and Senegal, flow through the southern region. A number of countries share border 
with Mali and includes Algeria in the north, Niger in the east, Burkina Faso in the south-
east, Cote D’Ivoire and Guinea in the south, and Mauritania and Senegal in the west. 
Distribution of HIV prevalence varies from one region to another. Based on two surveys the 
highest recorded prevalence is observed to be in the Bamako region, where majority of 
inhabitants live.  
A report of HIV/AIDS was first made in 1985 in Mali. In 2001, the Demographic and Health 
Survey indicated a prevalence of 1.7% among adults (Pichard, 1988; Ballo, 2001). This survey 
hinted that the prevalence in the general population could increase three-fold if appropriate 
preventive measures are not put in place to curtail the spread of the infection. Consequently, 
with a strong commitment from the government a National AIDS Program (NAP) was 
formed and by 2006 the rate had decreased to 1.3%. The NAP was again restructured in 2002 
by which time rates of HIV infection was higher among young women (mostly pregnant 
women with prevalence ≤5%) between the ages of 25 to 29 years than young men. Similarly, 
among the 30-34 years age group, women had 2.2% prevalence against 1% prevalence for 
men. Table 1 shows the distribution of HIV prevalence in Mali between the regions. Overall, 
prevalence is higher in the urban areas (1.3%) than in the rural (0.6%). Though there are 
poor records of transmission and prevalence rates, the survey in 2006 showed that sex 
workers were the highest risk group with 35.3% rates, followed by young street vendors 
(5.9%), drivers (2.5%), while casual workers and the unemployed youth shared the same 
rate (2.2%) (Samake, 2006).  
It is worthy of mention that Mali is a poor country with about 70% of the population in 
extreme poverty. In addition, a similar proportion, mainly women are illiterate. A number 
of socio-cultural practices such as excision and tattooing are commonly found among the 
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population. The 2006 sentinel study indicated that there was early onset of sexual activity 
among young women and in addition there is generally low condom use by young males 
between the ages of 15 and 24 years. These together posed a risk factor for infection among 
the young population in which 2 out of 3 did not believe in the existence of HIV/AIDS 
(Samake, 2006).  
 
ADMINISTRATIVE MAP OF MALI 
 
Fig. 1. Map of Mali showing the 8 administrative regions (Samake, 2006). 
 
Regions of Mali 
Prevalences
2001 2006 
Kayes 1.9 0.7
Koulikoro 1.9 1.2
Sikasso 1 0.6
Segou 1.9 1.3
Mopti 1.4 1.4
Gao 0.7 1.1
Tombouctou 0.7 0.5
Kidal 0.7 0.6
Bamako 2.5 1.9
Note: This table shows the differences between the two national surveys of HIV prevalence in the 
different regions of Mali. As can be seen HIV prevalence decreased in the period 2001 to 2006.  
Table 1. HIV prevalence in 2001 and 2006 from different administrative regions of Mali. 
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In 2001, the Malian initiative of access to antiretroviral therapy (IMAARV) was created. This 
initiative organizes, implements and follows up antiretroviral therapy in patients infected with 
HIV. The most important effort of the Malian government was to make free the distribution 
of antiretroviral drugs for all patients including diagnosis and follow up. This measure 
allowed the acquisition of regular data from different groups working in HIV field.  
Thus, the data presented in this chapter represents those from different groups working in 
Mali, and includes epidemiological data from the Malian health system and research 
reports. 
2.2 HIV prevalence among the educated & non-educated folk 
Although HIV epidemic is related to certain behaviors that exposes an individual to the 
virus and subsequently increases the risk of the individual to infection, unsafe behaviors are 
the main contributing factors to transmission of HIV in Mali. For instance, condom use 
among young males between the ages of 15 and 25 is around 30% and 14% for young 
women. Similarly, condom use is low among military personnel, truck drivers and vendors 
of all kinds. 
Given that knowledge about HIV is important in identifying and better understanding 
populations most at risk for HIV infection, the national control program embarked upon 
different strategies and campaigns to assess knowledge and behavior of students about HIV 
regarding the different routes of transmission. In the study that also assessed the prevalence 
and predictors of HIV infection among 950 high school and University students in three 
regions of Mali, namely, Bamako, Sikasso and Koulikoro, it was observed that the 
prevalence rate was respectively 3.6, 1.8, and 3.4%. Overall prevalence of HIV was 3.1% and 
both HIV-1 and 2 were circulating in the schools, although there was more HIV-1 (93.1%) 
than HIV-2. The study however, did not observe any association between HIV status and 
the following predictors: age, sex, marital status, religion, education level, ever had 
intercourse, current sexual partner, condom use at last sexual intercourse, casual sex and 
study site. By regression coefficient (1.25; p< 0.01) the study showed that the main 
significant predictor of HIV infection was knowledge of route of infection (White, 2009). 
Thus it demonstrated that the most feasible strategy for slowing down the HIV/AIDS 
epidemic is education towards risk reduction and prevention of infection. It is not known 
yet whether there have been follow up studies to understand why the students who had 
knowledge of the route of transmission of HIV infection were more at risk so that better and 
more effective strategies can be designed to prevent  future occurrence.  
2.3 HIV Infection in jail 
Few studies were conducted in the Malian prisons. This is particularly due to the strict 
government regulations that protect the occupants of these prisons. The prisoners are 
known to be at high risk for HIV infection because of unsafe behaviors in these places 
(Pichard, 1988). Thus knowledge of prevalence in this group has relevant impact on 
designing strategies for prevention in these areas. To this end, some studies have looked at 
attitude, risk behaviors and knowledge of HIV within jail population, and noted that most 
inmates of a jail had limited knowledge of the definition of HIV/AIDS. Only 2.7% knew that 
AIDS is an Acquired Immunodeficiency Syndrome and can be transmitted through body 
fluids and by sex. The study also showed limited knowledge of routes of transmission for 
both HIV and Sexually Transmitted Diseases (STDs), and only 7.5% of the study population 
knew their HIV status (TCHOUZOU, 2008).  
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Recommendations from this study led the national program against HIV/AIDS to initiate 
large campaigns in 2006, regarding the routes of transmission of HIV in order to educate 
people in different communities including prisoners. Topics covered in these campaigns 
included sexual transmission, intravenous drug use, mother-to-child transmission of HIV, 
risks from blood products and transfusion, organ donor or tissue transplantation  as well as 
risks of occupational exposures to the virus. Similarly, there is a need to conduct follow-up 
studies to determine the prevalence of HIV so that improved recommendations can be made 
for implementation, particularly in the jails. 
2.4 HIV prevalence among blood donors 
Whereas HIV overall prevalence in Mali is currently 1.3%, prevalence among blood donors 
is 2.6% (Diarra, 2009).  Estimates from the National Center of Blood Transfusion (Centre 
National de Transfusion Sanguine [CNTS], Bamako, Mali) indicate that this rate had risen 
from 3% in 1999 to 4.5% in 2009 (Tounkara, 2004; Tounkara, 2009) and decrease to 2.6% in 
2007 (Diarra, 2009). Young adults (between 18 and 25 years) accounted for 41% of overall 
blood donors. It is important to note that, 1.13% of the blood donors with HIV were also co-
infected with Hepatitis B virus (HBV) (Table 2). Of these, 88.5% are men (over 25 years of 
age), while young adults make up 43%. About 80% of the blood donors from the cohort at 
CNTS were recruited from family members of patients who need blood transfusion. From 
this cohort some studies have shown that majority of the HIV seropositive individuals had 
thrombocytopenia, with a platelet count lower than 150 x 103/mm3 (Tounkara, 2004). 
Compared to HIV seronegative individuals, the HIV infected had longer bleeding time, a 
diminution of the rate of prothrombin, and an elevated partial time for thromboplastin. 
Taken together, these data suggest a modification of hemostasis over the course of HIV 
infection (Tounkara A, 2004). Also, a proportion of blood donors were found to have human 
cytomegalovirus (HCMV). Among these, 89% were AIDS patients, 71% were HIV-infected 
and 58% were uninfected with HIV. About 40% of the blood donors co-infected with HIV 
and HCMV also had pneumonia compared to those infected with only HIV (Maiga, 2003; 
Tounkara, 2004). 
 
 HBV Status 
HIV Status Positive, n (%) Negative, n (%) Total, n (%) 
Positive 131 (1.13) 387 (3.34) 518 (4.47) 
Negative 1591 (13.73) 9483 (81.80) 11 074 (95.53) 
Total 1722 (14.86) 9870 (85.14) 11 592 (100) 
Abbreviations: HBV, hepatitis B virus; HIV, human immunodeficiency virus; n, number of donors; %, 
percentage of the specific cell based on the total number of donors (11 592). 
Note: This table represents HIV and HBV infection alone as well as the prevalence of co-infection 
among Malian Blood donors. 
Table 2. HIV/HBV Coinfection Frequency among Blood Donors in Mali 
Studying HIV prevalence among blood donors will help to refine strategies used in 
recruiting blood donors, and significantly reduce HIV transmission in the general 
population. 
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2.5 Circulating recombinants forms of HIV in Mali 
A lot of interest has been generated by the scientific community in seeking to understand 
the range of variability of HIV so that the spread of an epidemic can be tracked between 
different population and places, as well as develop strategies to control the virus. Firstly, 
HIV is thought to be the most variable virus, and its clinical characteristics alone are not 
sufficient to explain the outcomes of infection. In addition, it has subtypes with distinct 
geographic distribution and recombination can occur between and within subtypes (Korber, 
2003).  Thus creating a further increase in the genetic diversity in many parts of the world 
and thereby a complex challenge to control. As a result, the role of genetic variability in HIV 
infection has received extensive consideration both for understanding of the natural history 
of the disease and for developing strategies for control of the virus. Currently 9 subtypes 
have been identified worldwide in the HIV-1 group M (A, B, C, D, F, G, H, J and K). Viruses 
E and I in the envelope are recombinant strains (Peeters, 1999). In 2009 estimates showed 
that approximately 2.6 million [2.3 – 2.8 million] new infections were due to HIV-1 subtype 
non-B, and these were predominantly among infected individuals in the Americas, Western 
Europe, and in Australia (Report 2010 of UNAIDS). More than 50% of HIV infections 
worldwide are associated with the HIV-1 subtype C, with South Africa having the highest 
majority, while subtypes A and D are commonly found in East Africa. The prevalence of 
recombinant forms of HIV has been increasing, and in Europe it rose from 17% during the 
period 1996-1999 to 28% in the period 2000-2003 and again to 35% in 2006-2009. The most 
common recombinant strain in circulation in some regions of Africa and West Asia is the 
HIV-1 Circulating Recombinant Form (HIV-1 CRF).  
A number of studies have characterized subtypes in Mali and other West African states, and 
have noted that the recombinant CRF02_AG is the main HIV-1 infecting strain in this region. 
Sequencing analysis has revealed that early failures to Triomune ® (d4T/3TC/NVP) in 
adults occurred because the viruses in circulation were recombinant CRF02_AG (Marcelin, 
2007). Recent primary drug resistance studies conducted in Mali (in Bamako and Segou) on 
198 samples obtained from ARV-naive patients showed CRF02_AG to be the most prevalent 
strain, with respectively 70.5 and 72% occurring in 2005 and 2006 (Derache, 2008). A second 
recombinant strain was CRF06_cpx with 19.5% and 11% infections respectively occurring in 
the same period. Other subtypes and recombinants in circulation were also found, but with 
a lower prevalence in these two years. Overall, there was a greater genetic diversity in the 
year 2006 compared to 2005. Indeed, in 2005, two pure subtypes (C and G) and a 
recombinant (CRF01_AE) were found, while in 2006, three pure subtypes (A, F2 and G) and 
3 recombinants (CRF01_AE, CRF09_cpx and CRF18_cpx) were identified (Derache, 
2007). The prevalence of CRF02_AG appeared to be stable, while that of CRF06_cpx 
decreased, giving way to other subtypes, including CRF09_cpx and CRF18_cpx which are 
new strains in Mali. The recombinant CRF09_cpx, is a mosaic virus from different subtypes 
(A, F and G), and although it was first described in 2004, in West Africa, it is now the most 
predominant recombinant strain in the region. This recombinant appears to have structural 
similarities as well as important genetic distances like the first CRF02_AG isolated 
(McCutchan, 2004). As for the recombinant CRF18_cpx, this was first identified in 2005 in 
Cuba, but now, seems native to Central Africa. Indeed, it consists of various segments from 
the CRF13_cpx, CRF04_cpx and 36 other viruses, is predominantly found in Central Africa 
(Thomson, 2005). Similarly, a recent study in Mali found a subtype namely, CRF05_DF 
(Maiga, 2010). This subtype, CRF05_DF, was first described in Belgium in 2000 from a 
patient linked to the Democratic Republic of Congo (DRC) (Laukkanen, 2000). Thereafter, 
Casado and colleagues identified another strain in 2003 in the DRC (Casado, 2003).  
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Fig. 2. Phylogenetic analysis from different subtypes in Mali. Results are presented  for 
Bamako on the left and for Segou on the right. (a) Unrooted phylogenetic trees of  pol 
nucleotides sequences. Sequences from references strains appear in bold. Each colour  
corresponds to a subtype or CRF. (b) Graphic representation of subtypes repartition. (c) pol  
gene mosaic viruses (‘unknown U’ viruses), with recombination points and subtypes 
involved. (Derache, 2008) 
As seen from the phylogenetic data above (Fig. 1), Mali has a large genetic diversity of HIV-1 
viral strains and the potential to generate new recombinants. While evaluating antiretroviral 
resistance of HIV strains in Mali a recent study conducted among 746 ARV treatment-naive 
HIV-1 patients showed that the majority carried the CRF02_AG subtype CRF06_cpx (Maiga, 
2010). Indeed, many of the viruses sequenced in this study were either recombinant 
intersubtypes or had unique recombinant forms (URF). A large proportion 72%% of these 
were the recombinant CRF02_AG. It is therefore important to monitor the emergence and 
spread of new recombinants because the appearance of a particular polymorphism within a 
new recombinant could lead to resistance mutation profiles in individuals or a different 
response to antiretroviral therapy. For now, the CRF02_AG is believed to be the most 
prevalent (72%) in Mali and overall it appears to have similar characteristics to the subtype B. 
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The genetic variability of HIV viral strains involves genes encoding the viral enzymes, which 
are targets of therapeutic drugs. This variability occurs because of errors in viral reverse 
transcriptase. Knowledge of the genetic subtype as well as the inter-subtype recombinant 
nature of HIV-1 strains might be of crucial importance for the development of future HIV 
vaccine. Some substitutions of amino acids are found at high frequencies at positions involved 
in resistance to ARVs in subtype B. Thus, over 50% of non-B virus infecting in naive patients 
carry at least three PI resistance mutations, while it concerns only 8% of the virus subtype B 
(Holguin, 2002). To assess the impact of this polymorphism on resistance to ARVs, many 
phenotypic studies have been conducted on the gene for PR gene with many mutations of 
minor resistance in subtype non-B. Although many results conclude that patients infected with 
HIV-1 subtype non-B also respond well to treatment than patients infected by subtype B, some 
studies show a decreased sensitivity to certain subtypes IP. For example, the recombinant 
CRF02_AG, naturally bearing mutations K20I and M36I, replicates better in the presence of IP, 
thus reducing its sensitivity to these molecules, including NFV (Kinomoto, 2005). In addition, 
Perno et al demonstrated that the minor mutation M36I of PR gene, polymorphic in non-
subtype B was predictive of virological failure after 24 weeks of antiretroviral therapy 
containing a PI, in fact, appearance of major mutations L90M during virologic failure was 
associated with the presence of the mutation M36I (Perno, 2004). A study in Uganda also 
showed that mutations associated with resistance to NVP was detected more frequently 6-8 
weeks after delivery in women infected with subtype D than subtype A after taking a single 
dose of NVP in the context of PMTCT (Kiwanuka, 2008). The authors explain this result by a 
potential natural polymorphism of IT to push faster selection of resistance mutations to 
Nevirapine. A recent study conducted in Japan identified a new recombinant strain of HIV-2, 
CRF01_AB. Although no recombinant forms of HIV-2 have been found in Mali, there is a 
possibility that this new strain may soon be identified here, given that it was identified from 
samples obtained from Cote d’Ivoire (Ibe, 2010).  
2.6 HIV drug resistance in Mali 
The management of patients infected with HIV is complex and follows a long duration. It will 
therefore improve the quality of life of people living with HIV, if drug resistance is avoided. 
Several research studies on resistance mutations were performed in Mali. In 2007, Derache and 
colleagues evaluated the presence of resistance mutations in 98 naive patients receiving 
antiretroviral therapy, and showed the presence of K103N in two individuals. This mutation 
resulting in NNRTI resistance, render NVP or EFV inefficient (Derache, 2007). Similarly, 
another study estimated the presence of resistance mutations in 109 patients treated in Segou  
by Triomune ® (d4T +3 TC + NVP) in a median time of 8 months, and showed 11 cases of 
resistance to the presence of different mutations as follows: 2 cases of M184V alone, 1 case of 
Y181C alone, 8 cases including 5 associations Y181C + M184V, K103N + M184V + 2 and 1 
association G190A + M184V K101E + G190A (Marcelin, 2007). These data demonstrates the 
need for the management of early failures to drug treatments and shows the importance of 
using other NRTIs in second-line treatments. Based on the 2007 version of an algorithm of 
interpretation by International AIDS Society (IAS) Derache and colleagues showed an overall 
prevalence for primary resistance of 11.5% (made up of 1.5% for NRTIs (K219Q), 9% to 
NNRTIs (Y181C, K101E, V90I, A98G and V106I and V108I) and 1% for PI (L33F and M46L)) 
(Derache, 2008). These identified mutations corresponded to the treatments used except for the 
mutations V90I, A98G and V106I which were associated with resistance to TMC 125 or 
Etravirine according to the IAS algorithm. No significant difference between 2005 and 2006 in 
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the prevalence of primary resistance of different classes of antiretroviral drugs has been 
observed. A similar study of treatment-naive patients recently showed a higher prevalence of 
primary resistance (9.9%) than was previously reported by Derache and colleagues (Haidara, 
2010; Derache, 2008). So also have other studies reported late failures to drug treatment in Mali 
and in Burkina Faso with median treatment duration lasting 18 months (Sylla, 2008). Recently, 
two studies looked at resistance mutations among treatment-naïve patients in Mali. In the first 
study, 10% of patients failing second-line drug treatments were found to have failed therapy to 
all available drug molecules used in the country (Maiga, 2010). In the same study, resistance 
associated to ETR was found in ARV-naïve patients with HIV-1 subtype B. Previously, the 
genetic barriers to integrase inhibitors for HIV-1 subtype B had been compared to those of 
CRF02_AG and although they both have similar barriers, the CRF02_AG carried a higher 
genetic barrier at positions 140 and 151 of the integrase (Maiga, 2009). Thus, the finding in 
which ETR was implicated is important because it will facilitate the establishment of second 
and third line ARV treatments in a developing country such as Mali (Maiga, 2010). In the 
second study, of 57 HIV-2 treatment-naïve patients, 3 of 36 had a PR and RT-resistance 
mutation, implying that either resistant virus to these class strategy are circulating in Mali or 
the patients were taking ART without medical supervision. Of the remaining 21 patients, 1 had 
resistance mutations to both RT and PR, while a second had resistance to RT only. The 
presence of these mutations in both of these treatment-naïve patients indicates inadequate 
compliance to treatment (Oumar, 2010). 
Although there is the risk that resistant viruses are spread throughout the country, and 
thereby pose an additional public health challenge, currently there is not enough data at the 
national level on the transmission of resistant virus. Despite this, the data shown from the 
studies mentioned above indicate the magnitude of the problem which may limit 
therapeutic choices in a resource-limited country such as Mali. And because, resistance is a 
major concern for long-term treatment in this place, it is necessary to improve adherence to 
treatment as well as routine monitoring to avoid an escalation of the evolution of primary 
resistance. One approach to resolving this is to broaden genotypic testing for treatment 
failures, and have a wider range of antiretroviral drug regimen to cover cases involving 
resistant strains. Although individual classes of antiretroviral are low, overall primary 
resistance in Mali is high. Exceptions are the NNRTIs which are relatively high (9%) 
probably due to their frequent use. In the past at least, a single-dose of NVP was used for 
the prevention of mother to child transmission and needs monitoring.  
3. Conclusions/recommendations 
Considerable efforts have been made towards HIV prevention and treatment in Mali. 
Lessons learnt from some epidemiological data showed that the efforts must be sustained in 
order to make significant changes to the behavior of young adults regarding HIV infection 
in Mali. As shown the prevalence of HIV alone is variable between social groups. 
Surprisingly, the prevalence among those co-infected with HIV and HBV was so high that 
this particular group must be targeted for further education and counseling. Despite this, it 
must be remembered that the biggest challenge is the rising numbers in circulating 
recombinant forms of HIV due to the occurrence of several mutations resistant to 
antiretroviral drugs. Therefore in Mali, there is an urgent need to increase access to 
antiretroviral drugs. In addition, newer approaches must be developed to improve 
compliance as well as follow up monitoring of viral load levels of the patients. Also, it will 
www.intechopen.com
 
HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 56
be more useful if knowledge about HIV and the level and frequency of risk behaviors 
related to the transmission of HIV is stepped up as part of a national educational campaign, 
with the hope to change unsafe behaviors towards a better one.  
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